We investigated the effect of a fibrinolytic inhibitor, tranexamic acid, on blood loss and blood transfusion in knee arthroplasty by a randomised, double-blind study of 86 patients. A dose of 10 mg/kg body-weight of either tranexamic acid or placebo was given intravenously shortly before the release of the tourniquet, and repeated three hours later. The mean total blood loss was 730 ± 280 ml in the tranexamic acid group as against 1410 ± 480 ml in the placebo group (p < 0.001).
As the risks of allogenic blood transfusion have been revealed, programmes of blood conservation in orthopaedic surgery have become more desirable. The most direct approach is the reduction of peroperative and postoperative blood loss. Various surgical and anaesthetic methods are used, but blood conservation can also be achieved by pharmacological means (Hunt 1991; Royston 1993) .
After any surgery, the fibrinolytic system is transiently activated (Risberg 1985) , and the use of a tourniquet also induces local fibrinolysis in the operated limb (Fahmy and Patel 1981) . This increased fibrinolytic activity may increase blood loss after knee arthroplasty, at least during the first postoperative hours. Tranexamic acid inhibits fibrinolysis by blocking the lysine-binding sites of plasminogen to fibrin (Nilsson 1980) . It has been used in general urological, gynaecological, and thoracic surgery to reduce blood loss (Verstraete 1985; Horrow et al 1990; Åstedt, Sheppard and Soma 1991) .
We have used tranexamic acid to reduce blood loss in total knee arthroplasty since 1988. An earlier retrospective study indicated that this reduced both blood loss and the amount of blood needed for transfusions (Benoni et al 1994 . Recently, two other studies have shown that tranexamic acid and another fibrinolytic inhibitor, aprotinin, can reduce blood loss in knee and hip arthroplasty (Janssens et al 1994; Hiippala et al 1995) .
We aimed to explore further the potential blood-saving effect of tranexamic acid in total knee arthroplasty.
PATIENTS AND METHODS
Our study was designed to be prospective, randomised and double-blind, and was approved by the Ethics Committee of the Medical Faculty at Lund University. All patients gave their informed consent. From our previous retrospective study, we calculated that 96 patients would be sufficient to confirm the mean blood-reducing effect of 340 ml found in that study, with 5% significance and 80% power. This number included an allowance for drop-outs. Because both cemented and uncemented knee replacements are used in our department, we included 48 of each type, randomised separately.
Randomisation into blocks of 12 was done by an independent pharmacologist who was not otherwise engaged in the study. Pairs of ampoules, each containing 10 ml of either the active substance (Cyklokapron 100 mg/ml; Pharmacia, Stockholm, Sweden) or the placebo (physiological saline) were numbered and packed in envelopes which were opened by the anaesthetist before administration. These ampoules could be identified only by their numbers, and the randomisation code was known only to the independent pharmacologist. The code was not broken until the end of the study and until all data had been corrected and included in the database.
The criteria for inclusion in the trial were: 1) no history of bleeding disorders or warfarin medication; 2) a diagnosis of osteoarthritis or aseptic bone necrosis, but not of rheumatoid arthritis; 3) primary, unilateral, bicompartmental knee arthroplasty; 4) either both or no components cemented; 5) continuous epidural anaesthesia; and 6) the use of only balanced electrolyte solutions and/or albumin for plasma volume restitution.
Two patients dropped out of the trial, one because the ampoules were accidentally broken, and the other because of the use of general anaesthesia. Before the code was broken, we decided to exclude another eight patients, for various reasons. In three only one component had been cemented, in three tricompartmental arthroplasty had been performed, in one non-vacuum drains had been used and in one dextran had been given postoperatively. This left 43 patients for evaluation in each randomisation group. Previous operations had been performed on 17 patients for high tibial osteotomy and on one for transposition of the tibial tubercle (Table I ).
All the patients had been requested to cease taking any non-steroidal anti-inflammatory agents (NSAIDs) for one week before surgery, but when specifically asked on the day before operation, 13 of them admitted to mostly sporadic intake of NSAIDs during this time. For reasons which will be discussed later these patients were accepted into the study. All patients received low-molecular-weight heparin, as thromboprophylaxis, either dalteparinsodium (Fragmin, Pharmacia, Stockholm, Sweden), 5000 units (n = 49) or enoxaparin (Klexane; Rhone-Poulenc Rorer, Paris, France), 40 mg (n = 37), as a daily subcutaneous injection for seven to ten days, starting the evening before surgery. A dose of cloxacillin (Ekvacillin; Astra, Södertälje, Sweden) 2 g was given intravenously shortly before operation and two more doses of 1 g were given at six and 12 hours after the first dose. For patients with an allergy to penicillin, clindamycin was used.
After premedication, analgesia was achieved in all patients by continuous epidural anaesthesia through an indwelling catheter, which was removed in the early morning of the first postoperative day. No patient received NSAIDs during the first two postoperative days. All the operations were performed in a bloodless field. After elevation of the limb and exsanguination with an Esmarch bandage, a tourniquet was inflated to 350 to 400 mmHg. At the end of the operation, the tourniquet was deflated and major bleeding was contro
The PFC total knee prosthesis was used in all cases and inserted according to the manual supplied by the manufacturer (Johnson and Johnson Orthopaedics Inc, Raynham, Massachusetts). Any variation in surgical methods, such as synovectomy, soft-tissue release and plugging the femoral canal was recorded. Palacos cement with gentamicin (Schering-Plough Int, Kenilworth, New Jersey) was used for fixation of the cemented arthroplasties. The operations were performed by eight different surgeons on our staff; 61 of them were undertaken by three surgeons who did 17 to 23 operations each, and another two carried out a total of 18 operations.
In each knee, one intra-articular and one subcutaneous drain (both 14 gauge) were used and connected to two highvacuum drain bottles (Medinorm AG, Quiershied, Germany). In one patient only one intra-articular drain was used because of very thin subcutaneous tissue. In one patient in the placebo group, blood coagulated in the drains, causing seepage from the drainage hole. Six patients pulled out their drains before the scheduled time. In five others the record of blood loss at 24 hours was omitted before breaking the randomisation code, either because the measurement had not been recorded at the proper time or was listed as less than the preceding value and thus considered to be erroneous. In these patients, records for blood loss were included for as long as the drain readings were considered relevant, but omitted thereafter.
The dose of tranexamic acid of 10 mg/kg body-weight, maximum 1 g = 10 ml, or an equivalent volume of placebo, was given as a slow intravenous injection towards the end of the operation at a median time of 12 minutes (1 to 40) before deflation of the tourniquet. This dose was repeated after three hours from the other ampoule of the pair provided in an envelope.
For patients with severe postoperative bleeding, an extra dose of tranexamic acid was given, without breaking the randomisation code. The cut-off values for this level of blood loss were set at >500 ml of blood lost via the drains within one hour or >1000 ml within four hours after the end of the operation. The decision to administer this dose of tranexamic acid was made by the anaesthetist in charge. Fifteen patients were given this extra dose at 1 to 5.7 hours (median 2.8) after the operation entirely because of heavy blood loss. All these patients were in the original placebo group and are referred to as the 'placebo + extra' group in the results and discussion (see Fig. 2 ).
The blood loss at the end of surgery was recorded by measuring the volume in the suction apparatus and estimating that lost in the swabs. Postoperative blood loss was recorded from the drain bottles at 1, 4, 8 and 24 hours postoperatively and on drain removal at 24 to 33 hours (median 28). In another study we found that the volume scaling in this type of drain gave a mean error of +1 ml (95% reference interval -4 to +6 ml) (Benoni, unpublished data) .
The blood Hb concentrations were determined at admission, at the end of the operation, one hour postoperatively and on the mornings of the first, second, fourth and seventh postoperative days. On admission, the platelet count, the activated partial thromboplastin time (APTT) and the prothrombin complex test (PT) were also determined and found to be within normal values in all cases.
The indication for blood transfusion in our department is not set at a specific value for Hb concentration or haematocrit levels. Each transfusion is prescribed with regard to the patient's cardiovascular history, present status, fall in Hb level, rate of blood loss and age. As a rule of thumb, we consider that blood transfusion is indicated at a Hb concentration of below 85 to 100 g/l. Blood transfusions were recorded as the number of Sagman units transfused. A Sagman unit includes approximately 330 ml of erythrocyte concentrate with a haematocrit of about 60%, prepared from 450 ml of donor blood with the addition of 100 ml of Sagman solution (Högman et al 1978) .
We measured the knee circumference just above the patella on the day before surgery and at three days after operation. Records were made of all wound complications such as the formation of haematoma, drainage from wound or drain sites, and any signs of infection or delayed healing. The range of motion was recorded at a follow-up visit approximately six weeks after the operation.
We used no routine screening for thrombosis, but all clinically suspected thromboembolic complications in the first six weeks were investigated using ascending phlebography and/or pulmonary scintigraphy. Statistics. For tests of differences between quantitative data, two-sided t-tests were used. Differences between proportions and qualitative data were tested by the chi-squared test with Yates' correction and the Mann-Whitney U test. Analysis of variance was used to analyse variables which could influence postoperative blood loss. Analyses were done using Statistica, release 4.5 (StatSoft, Tulsa, Oklahoma). In the text, data are presented as mean ± standard deviation (SD) and p values of <0.05 are considered significant.
RESULTS
Details of the patients in the tranexamic acid and placebo groups are shown in Table I . There were no significant differences between them as regards the data presented.
The peroperative blood loss was similar in the prophylactic and in the placebo group (210 ± 140 v 210 ± 130 ml). The mean blood loss in the drains at removal was 520 ± 230 ml in the prophylactic group and 1210 ± 480 ml in the placebo group (p < 0.001). The mean total blood loss was 730 ± 280 ml in the prophylactic group and 1410 ± 480 ml in the placebo group (p < 0.001). Since the drains were not retained for the same period of time in all patients, further comparisons concerning blood loss are limited to the scheduled reading times and values at drain removal were omitted. The distribution among the patients of the blood loss via the drains after 24 hours is shown in Figure 1 .
As reported above, 15 patients, all in the placebo group, received a late dose of tranexamic acid because of heavy blood loss. Not all patients meeting the criteria for extra administration of tranexamic acid were actually given this dose. In total, 19 patients from the placebo group and one from the prophylactic group fulfilled these criteria (p < 0.001). In spite of receiving a late dose of tranexamic acid, the 15 patients in the placebo + extra group continued to bleed significantly more than the remaining patients in the placebo group up to eight hours after the operation (p = 0.04). To illustrate this, we have shown the accumulated, postoperative blood loss for these two placebo sub-groups separately in Figure 2 . The influence of the use of cement and of tranexamic acid on blood loss at 24 hours after the operation is cross-tabulated in Table II .
Analysis of variance showed that the prophylactic administration of tranexamic acid was the dominating determinant for postoperative blood loss (Table III) . The next most important factors, with p values from 0.054 to 0.072, were the use of synovectomy, the type of prophylaxis against thrombosis and recent intake of NSAIDs. Plugging of the femoral canal was not a significant factor; neither was the use of cement. The interactive effect of no cement and no prophylactic tranexamic acid appeared to be associated with an increased postoperative blood loss (Table II) ; this was not significant, however, in the variance analysis (Table  III) .
Blood Hb concentrations before and after surgery are shown in Figure 3 . The differences between the prophylactic and placebo groups are significant from day 1 onwards (p < 0.001). Eight patients in the prophylactic group received 1 to 2 blood transfusions each as compared with 24 patients receiving 1 to 3 units each in the placebo group (p < 0.001). The total number of transfused Sagman units was 12 in the prophylactic group of 43 patients as against 40 in the placebo group of 43 (p = 0.002).
At our hospital, one Sagman unit of blood costs 512 SEK (51 GBP). The price of one ampoule of Cyklokapron, containing one gram of tranexamic acid, is 42 SEK (4 GBP). The total cost of blood transfusions plus tranexamic acid was 9756 SEK (976 GBP) in the whole prophylactic group against 21 110 SEK (2111 GBP) in the whole placebo group.
The increase in knee circumference between preoperative and postoperative measurements was 2.1 ± 4 cm in the prophylactic group and 2.7 ± 2.9 in the placebo group (NS). There was no significant difference in the range of motion at Hours after operation Blood loss (ml) Fig. 2 Accumulated blood loss through the drains in the prophylactic, placebo and placebo + extra groups (mean ± SEM). The numbers were 86 at 1 and 4 hours, 84 at 8 hours and 74 at 24 hours.
six weeks after surgery (90 ± 13° v 86 ± 14°). There were seven recorded wound haematomas in the prophylactic group as against four in the placebo group. In the prophylactic group secretion from the drain sites occurred in three and superficial infection in two patients as against two and no patients, respectively, in the placebo group. Because of clinical suspicion of deep-venous thrombosis, phlebography was performed in nine patients from each group. The diagnosis was confirmed in four patients in the prophylactic group and in three in the placebo group. One patient in the placebo group had pulmonary embolism, which was confirmed on pulmonary scintigraphy. One patient in the prophylactic group complained of chest pain and showed hypotension three days after surgery. A ventilation-perfusion pulmonary scan showed a low probability for pulmonary embolism. Pulmonary angiography was not performed, but on clinical grounds she was treated with lowmolecular-weight heparin and warfarin. She later developed a wound haematoma, necessitating surgical evacuation after four weeks. After this operation she again experienced chest pain. A repeated lung scan gave the same result and in this context, the patient was not registered as having had a pulmonary embolism.
DISCUSSION
We have investigated the effect of a once-repeated dose of tranexamic acid on blood loss and on blood transfusion required after total knee arthroplasty. From our previous study and from other reports we found that factors such as the number of cemented components (Mylod et al 1990; Collins et al 1991; , plugging of the femoral canal (Raut, Stone and Wroblewski 1993) and method of anaesthesia (Modig et al 1983; Modig and Karlström 1987) could all influence blood loss in orthopaedic operations. Carlin et al (1980) consider that the administration of dextran decreases postoperative fibrinolytic inhibition after total hip arthroplasty, a finding which has potential influence on our results.
In designing our study we tried to control these factors as much as possible. We included only operations under epidural anaesthesia. Cemented and uncemented arthroplasties were randomised separately and albumin solution was used instead of dextrans or hydroxyethyl starch solutions for volume expansion. The sample size was calculated from our previous retrospective study (Benoni et al 1994 , but our new results indicate a blood-saving effect of almost twice that found in the earlier study with a considerable level of statistical significance (Table III) . This increased effect may have resulted from the use of a repeated dose of tranexamic acid in addition to the elimination of some confounding factors. Table II shows that the use of cement seems to have reduced blood loss in the placebo group but not significantly in the prophylactic group. The reason may be that prophylactic tranexamic acid is so effective in reducing blood loss from the fibrinolytically active bone marrow (Björkman and Nilsson 1961 ) that the additional plugging of the marrow sinusoids by cement is of minor importance.
Two factors with a potential effect on blood loss were not strictly controlled: plugging the guide hole in the femoral canal and the use of NSAIDs. Plugging the femoral canal during the operation has been reported to reduce blood loss in knee arthroplasty (Raut et al 1993) , but this was not confirmed in our study. Not all of our surgeons used a femoral plug but the frequency of plugging was equal in the two treatment groups, and therefore any effect on bleeding was the same.
The influence of NSAIDs on blood loss has been disputed (Kenny 1992) . Aspirin has been shown to increase bleeding complications after cholecystectomy (Flordal and Sahlin 1993) and blood loss in cardiovascular surgery (Levy 1994) . We asked our patients to avoid any intake of NSAIDs for at least one week before operation. Nevertheless, 13 patients admitted that they had used NSAIDs in this period. Our previous study included patients with rheumatoid arthritis, who were generally allowed to continue to take their NSAID medication; they had no greater blood loss than patients with osteoarthritis who were supposed to avoid anti-inflammatory drugs . Also, in our experience, many of our patients frequently use salicylates for occasional minor pains in a rather casual way and even in the group which denied NSAID intake some patients may have used aspirin but had forgotten afterwards. For these reasons we decided to accept patients who admitted recent NSAID intake to the trial and to register and analyse the potential impact on blood loss. Our results suggest that NSAIDs may have some effect on blood loss in knee arthro- Blood Hb concentrations before and after surgery in the prophylactic and placebo groups (mean ± SEM) (Adm, at admission to hospital; Op end, at the end of the operation; 1 hour, at one hour after the end of the operation; Day, in the morning of the first, second, fourth and seventh postoperative days).
plasty, but this was not significant in our analysis of variance. These patients were equally distributed between the two groups, and do not alter our conclusions about the effect of tranexamic acid.
Our results indicate that the administration of tranexamic acid gives a significant reduction of blood loss in knee arthroplasties. As in earlier studies, this reduction is confined to postoperative loss; peroperative bleeding is not affected (Hedlund 1969; Benoni et al 1994 Hiippala et al 1995) . The reduction in mean loss may be caused either by a proportional reduction of blood loss in all patients or by greater reduction in a subgroup of patients which would otherwise have a very large blood loss, presumably because of a high fibrinolytic capacity. As shown in Figure 1 and 2, both mechanisms seem to be relevant: some patients in the placebo group had a blood loss within the first postoperative hour that was significantly higher than in the remaining patients, both in the placebo and in the prophylactic group. These heavy bleeders were virtually eliminated from the prophylactic group.
Figure 2 also shows that tranexamic acid has little effect when it is given as a treatment after heavy blood loss. If there had been a substantial effect, the rate of blood loss would have been expected to decrease after three hours postoperatively, when most patients received their extra dose of tranexamic acid. The rate of bleeding between four and eight hours in patients given 'placebo + extra' treatment continued to exceed the rate for both the prophylactic group and the remaining placebo group. Ali and Landymore (1994) have pointed out that this lack of effect is probably because fibrinolytic activation is a cascade process that is most easily inhibited in its earlier phases. Horrow, Strong and Van Riper (1994) consider that the early blockade of tranexamic acid on plasmin receptors or platelets may also be important in reducing postoperative blood loss.
The reduction in blood loss which we found in our prospective study was greater than that in our previous retrospective review (Benoni et al 1994 and about the same as that reported by Hiippala et al (1995) . The total blood loss for both study and control patients, however, was less than in the two previous studies. This discrepancy may be due to differences in surgical and anaesthetic techniques: in the previous studies, the administration of colloids, with their potential effect on blood loss, differed between study and control patients. This possible source of error was decreased in our prospective work.
In contrast to some other studies (Cushner and Friedman 1991; Lotke et al 1991; Hiippala et al 1995) , we also controlled the timing for the recording of blood loss. In our study, all the drains were removed in the afternoon of the first postoperative day, but because the surgery was at different times of the day, they remained in place for from 24 to 33 hours in different patients. We read the volume of drainage at specific times after surgery to avoid this error. We found that the mean blood loss between the 24-hour recording and the removal of the drains was 50 ml, but the range was 0 to 380 ml which shows that the error may be substantial in individual cases. There was, however, no statistically significant difference between the times for drain removal for the prophylactic and placebo groups (Table I) .
In the prophylactic group, both the total number of blood transfusions and the number of patients needing blood transfusion were reduced to about one-third of those in the placebo group. Despite this difference, postoperative Hb concentrations were significantly higher in the prophylactic group. This reduction in the number of blood transfusions is greater than that reported by Hiippala et al (1995) , although they transfused both study groups to the same postoperative Hb concentration. Comparisons are difficult because the indications for blood transfusions were different in the two studies.
We did not routinely conduct screening for thrombosis in our study. Previous research on tranexamic acid and thrombosis has failed to show any thrombogenic effect, even in patients who were treated for several days or even weeks (Becker and Borgström 1968; Gordon-Smith, Hickman and El Masri 1972; Hedlund 1975; Bekassy and Åstedt 1990) . This may be due to the fact that fibrinolytic activity in vein walls is not affected by tranexamic acid (Åstedt, Liedholm and Wingerup 1978) . Eriksson et al (1988) have shown that thrombosis prophylaxis using low-molecular-weight heparin delayed the onset of thromboses to the fourth or fifth postoperative day. For these reasons we consider it highly unlikely that we would have been able to show any thrombogenic effect of the administration of tranexamic acid during the first three hours after knee arthroplasty.
As shown in numerous studies, the fibrinolytic response after trauma is biphasic (Risberg 1985; Eriksson 1991) with an increased activity during the first hours, followed by a shutdown that peaks at about 24 hours (Kluft et al 1985) . After knee arthroplasty the early post-traumatic fibrinolysis is further augmented by that induced by the tourniquet (Fahmy and Patel 1981) . We have previously shown that the dose regimen which we used maintains a therapeutic plasma concentration of tranexamic acid for approximately eight hours (Benoni, Björkman and Fredin 1995) . Since 60% of the total blood loss via the drains in the prophylactic group and 80% in the placebo group have occurred within eight hours, our current dosage seems to be an adequate compromise between fibrinolytic inhibition and the risk of inducing an augmented fibrinolytic. shutdown.
